• Cat-intel
  • MedIntelliX
  • Resources
  • About Us
  • Hero Background
    English
    Chinese
    French
    Japanese
    Korean
    German
    Spanish

    Silent Heart Attack Market Share

    ID: MRFR/Pharma/3563-HCR
    110 Pages
    Rahul Gotadki
    October 2025

    Silent Heart Attack Market Research Report Information By Diagnosis (CT, MRI, ECG, Blood Tests), Treatment (Medications, Coronary Angioplasty And Stenting, Coronary Artery Bypass Surgery), End-User (Hospital, Clinic, Diagnostic Center) -  Global Forecast till 2035

    Share:
    Download PDF ×

    We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

    Silent Heart Attack Market Infographic
    Purchase Options

    Market Share

    Silent Heart Attack Market Share Analysis

    Tailoring demonstrative developments for early detection is a critical system. Organizations put resources into cutting edge innovations, like sensitive biomarkers and imaging modalities, to detect silent heart attacks in their beginning phases, empowering convenient mediation and worked on quiet results. Remaining at the front line of clinical development is fundamental. Organizations put resources into innovative work to present inventive treatments that advance myocardial recuperation after a silent heart assault, tending to the necessities of patients who may not display clear side effects. Investigating open doors for worldwide extension is urgent in the Silent Heart Assault market. Organizations products and administrations to meet territorial varieties in healthcare practices, social inclinations, and administrative landscapes to guarantee effective market entrance on a worldwide scale. Utilizing telemedicine and remote observing administrations is a cutting-edge approach. Organizations coordinate advancements that empower far off cardiology conferences, working with progressing observing and support for people who might have encountered silent heart attacks. Guaranteeing moderateness of silent heart assault medicines is vital. Organizations plan to make their symptomatic devices and restorative mediations open to a more extensive segment, frequently through organizations with protection suppliers or executing valuing models that think about understanding monetary limits. Continuous improvement is accomplished through criticism from patients, healthcare suppliers, and different partners. Organizations actively look for contribution to refine and improve their products and administrations, guaranteeing they remain receptive to the advancing requirements of people affected by silent heart attacks.

    Author
    Rahul Gotadki
    Assistant Manager

    He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

    Leave a Comment

    FAQs

    What is the expected growth rate of the global silent heart attack market?

    silent heart attack market is expected to register 7.14% CAGR from 2024 to 2032.

    Which is the biggest driver of the global silent heart attack market?

    silent heart attack market is driven by high incidence of cardiovascular diseases.

    What factors can restrain the global silent heart attack market?

    High costs of diagnosis of heart conditions and lack of skilled professionals are factors which can hamper the global silent heart attack market.

    Which region can dominate the global silent heart attack market?

    The Americas can dominate the global silent heart attack market till 2032 due to rising cases of cardiovascular diseases.

    Name the notable players of the global silent heart attack market?

    Toshiba Medical Systems Corporation, Merck & Co., Takeda Pharmaceutical Company Limited, Bayer, Boehringer Ingelheim GmbH, Bionet, Midmark Corporation, Johnson & Johnson, United Therapeutics Corporation, Pfizer, Daiichi Sankyo Company Limited, Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, Actelion Pharmaceuticals Ltd., Schiller AG, AstraZeneca plc, Sanofi, Welch Allyn, Koninklijke Philips N.V., Novartis AG, and Siemens are notable players of the global silent heart attack market.

    Market Summary

    The Global Silent Heart Attack Market is projected to grow significantly from 5.16 USD Billion in 2024 to 15.0 USD Billion by 2035.

    Key Market Trends & Highlights

    Silent Heart Attack Key Trends and Highlights

    • The market is expected to experience a compound annual growth rate of 10.21 percent from 2025 to 2035. By 2035, the market valuation is anticipated to reach 15.0 USD Billion, indicating robust growth potential. In 2024, the market is valued at 5.16 USD Billion, reflecting the current demand for silent heart attack awareness and treatment. Growing adoption of advanced diagnostic technologies due to increasing awareness of silent heart attacks is a major market driver.

    Market Size & Forecast

    2024 Market Size 5.16 (USD Billion)
    2035 Market Size 15.0 (USD Billion)
    CAGR (2025-2035) 10.21%
    Largest Regional Market Share in 2024 latin_america)

    Major Players

    <p>Siemens (U.S.), Schiller AG, Midmark Corporation, Koninklijke Philips N.V. (Japan), Bionet (Korea), Welch Allyn (U.S.), Toshiba Medical Systems Corporation (Japan), AstraZeneca plc (U.K), Pfizer (U.S.), Sanofi (France), Merck &amp; Co. (U.S.), Daiichi Sankyo Company Limited, Novartis AG (Germany), Bayer (Germany), Takeda Pharmaceutical Company Limited (Japan), Boehringer Ingelheim GmbH (Germany), Astellas Pharma Inc. (Japan), Johnson &amp; Johnson (U.S.), United Therapeutics Corporation (U.S.), Actelion Pharmaceuticals Ltd. (Switzerland), F. Hoffmann-La Roche Ltd (Switzerland)</p>

    Market Trends

    <p>The increasing prevalence of silent heart attacks, often undetected until significant damage occurs, underscores the urgent need for enhanced public awareness and preventive measures in cardiovascular health.</p>

    Centers for Disease Control and Prevention (CDC)

    Silent Heart Attack Market Market Drivers

    Market Growth Projections

    The Global Silent Heart Attack Market Industry is poised for remarkable growth, with projections indicating a market value of 5.16 USD Billion in 2024 and an anticipated increase to 15.0 USD Billion by 2035. This growth trajectory suggests a compound annual growth rate of 10.21% from 2025 to 2035, highlighting the increasing recognition of silent heart attacks as a critical health issue. Factors contributing to this growth include advancements in diagnostic technologies, rising awareness, and an aging population. The market's expansion reflects a broader commitment to improving cardiovascular health outcomes globally.

    Government Initiatives and Funding

    Government initiatives and funding aimed at cardiovascular health are pivotal in shaping the Global Silent Heart Attack Market Industry. Various health departments are allocating resources to research, prevention, and treatment programs focused on heart health. These initiatives often include public awareness campaigns, subsidized screenings, and funding for innovative research. Such support not only enhances the understanding of silent heart attacks but also encourages the development of new treatment modalities. As a result, the market is likely to witness substantial growth, with projections indicating a rise to 15.0 USD Billion by 2035, reflecting the impact of these governmental efforts.

    Advancements in Diagnostic Technologies

    Technological advancements in diagnostic tools are significantly influencing the Global Silent Heart Attack Market Industry. Innovations such as advanced imaging techniques and wearable health monitors enable early detection of heart conditions that may otherwise go unnoticed. These technologies facilitate timely interventions, potentially reducing mortality rates associated with silent heart attacks. The integration of artificial intelligence in diagnostic processes further enhances accuracy and efficiency. As the market evolves, the anticipated growth to 15.0 USD Billion by 2035 underscores the critical role of these advancements in improving patient outcomes and driving industry expansion.

    Aging Population and Increased Risk Factors

    The Global Silent Heart Attack Market Industry is notably impacted by the aging population, which is associated with a higher prevalence of cardiovascular diseases. As individuals age, the risk factors for silent heart attacks, such as hypertension and diabetes, become more pronounced. This demographic shift necessitates increased healthcare resources and interventions tailored to older adults. The market's projected compound annual growth rate of 10.21% from 2025 to 2035 reflects the urgent need for effective management strategies targeting this vulnerable population. Consequently, healthcare providers are focusing on preventive measures to mitigate risks and enhance quality of life.

    Increasing Awareness of Silent Heart Attacks

    The Global Silent Heart Attack Market Industry is experiencing growth driven by heightened awareness regarding silent heart attacks. Educational campaigns by health organizations emphasize the importance of recognizing risk factors and symptoms, even when they are not overtly present. This awareness is crucial, as silent heart attacks can lead to severe complications if left undetected. As individuals become more informed, they are more likely to seek preventive measures and screenings, contributing to market expansion. The projected market value of 5.16 USD Billion in 2024 reflects this growing consciousness, indicating a shift towards proactive health management.

    Rising Incidence of Lifestyle-Related Diseases

    The prevalence of lifestyle-related diseases, including obesity and diabetes, is a significant driver of the Global Silent Heart Attack Market Industry. Poor dietary habits, sedentary lifestyles, and increased stress levels contribute to the rising incidence of cardiovascular conditions. As these lifestyle factors become more common, the likelihood of silent heart attacks increases, prompting healthcare systems to adapt. Public health initiatives aimed at promoting healthier lifestyles are essential in addressing this issue. The market's growth trajectory, with an expected value of 5.16 USD Billion in 2024, indicates a response to the urgent need for effective interventions in lifestyle management.

    Market Segment Insights

    Regional Insights

    Key Companies in the Silent Heart Attack Market market include

    Industry Developments

    Future Outlook

    Silent Heart Attack Market Future Outlook

    <p>The Silent Heart Attack Market is projected to grow at a 10.21% CAGR from 2024 to 2035, driven by increasing awareness and advancements in diagnostic technologies.</p>

    New opportunities lie in:

    • <p>Develop AI-driven diagnostic tools for early detection of silent heart attacks. Expand <a href="https://www.marketresearchfuture.com/reports/telehealth-market-900">telehealth</a> services to monitor at-risk populations remotely. Invest in educational campaigns to raise awareness about silent heart attack symptoms.</p>

    <p>By 2035, the Silent Heart Attack Market is expected to be robust, reflecting heightened awareness and improved healthcare solutions.</p>

    Market Segmentation

    Intended Audience

    • Medical Device Manufacturers
    • Medical Device Suppliers
    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors

    Key Players in the Silent Heart Attack Market

    • Siemens (U.S.)
    • Schiller AG
    • Midmark Corporation
    • Koninklijke Philips N.V. (Japan) 
    • Bionet (Korea)
    • Welch Allyn (U.S.)
    • Toshiba Medical Systems Corporation (Japan)
    • AstraZeneca plc (U.K)
    • Pfizer (U.S.)
    • Sanofi (France)
    • Merck & Co. (U.S.)
    • Daiichi Sankyo Company Limited
    • Novartis AG (Germany)
    • Bayer (Germany)
    • Takeda Pharmaceutical Company Limited (Japan)
    • Boehringer Ingelheim GmbH (Germany)
    • Astellas Pharma Inc. (Japan)
    • Johnson & Johnson (U.S.)
    • United Therapeutics Corporation (U.S.)
    • Actelion Pharmaceuticals Ltd. (Switzerland) 
    • F. Hoffmann-La Roche Ltd (Switzerland)
    • Medical Device Manufacturers
    • Medical Device Suppliers
    • Medical Research Laboratories
    • Research and Development (R&D) Companies
    • Market Research and Consulting Service Providers
    • Potential Investors

    Report Scope

    Attribute/MetricDetails 
    Market SizeUSD 12.23 Billion by 2032 
    CAGR7.14% (2024-2032) 
    Base Year  2023 
    Forecast Period  2024-2032 
    Historical DataMarket Size 20234.53 (USD Billion)
    Forecast UnitsMarket Size 20245.16 (USD Billion)
    Report CoverageMarket Size 203212.23 (USD Billion)
    Segments CoveredCompound Annual Growth Rate (CAGR)7.14 % (2024 - 2032)
    Geographies CoveredReport CoverageRevenue Forecast, Competitive Landscape, Growth Factors, and Trends
    Key VendorsBase Year2023
     Market Forecast Period2024 - 2032
     Historical Data2019 - 2023

    FAQs

    What is the expected growth rate of the global silent heart attack market?

    silent heart attack market is expected to register 7.14% CAGR from 2024 to 2032.

    Which is the biggest driver of the global silent heart attack market?

    silent heart attack market is driven by high incidence of cardiovascular diseases.

    What factors can restrain the global silent heart attack market?

    High costs of diagnosis of heart conditions and lack of skilled professionals are factors which can hamper the global silent heart attack market.

    Which region can dominate the global silent heart attack market?

    The Americas can dominate the global silent heart attack market till 2032 due to rising cases of cardiovascular diseases.

    Name the notable players of the global silent heart attack market?

    Toshiba Medical Systems Corporation, Merck &amp; Co., Takeda Pharmaceutical Company Limited, Bayer, Boehringer Ingelheim GmbH, Bionet, Midmark Corporation, Johnson &amp; Johnson, United Therapeutics Corporation, Pfizer, Daiichi Sankyo Company Limited, Astellas Pharma Inc., F. Hoffmann-La Roche Ltd, Actelion Pharmaceuticals Ltd., Schiller AG, AstraZeneca plc, Sanofi, Welch Allyn, Koninklijke Philips N.V., Novartis AG, and Siemens are notable players of the global silent heart attack market.

    1. Definition
      1. Scope of the Study
        1. Research Objective
        2. Assumptions
        3. Limitations
      2. Introduction
      3. Primary Research
      4. Secondary research
      5. Market Size Estimation
      6. Drivers
      7. Restrains
      8. Opportunities
      9. Challenges
      10. Macroeconomic Indicators
      11. Technology Trends & Assessment
      12. Porters Five Forces Analysis
        1. Bargaining Power of Suppliers
        2. Bargaining Power of Buyers
        3. Threat of New Entrants
        4. Threat of Substitutes
        5. Intensity of Rivalry
      13. Value Chain Analysis
      14. Investment Feasibility Analysis
      15. Pricing Analysis
    2. Chapter 6. Global Silent Heart Attack Market, by Diagnosis
      1. Introduction
      2. Cardiac computerized tomography
      3. Market Estimates & Forecast, 2020 – 2027
      4. magnetic resonance imaging
      5. Market Estimates & Forecast, 2020 – 2027
      6. electrocardiogram
      7. Market Estimates & Forecast, 2020 – 2027
      8. echocardiogram
      9. Market Estimates & Forecast, 2020 – 2027
      10. Blood Test
      11. Market Estimates & Forecast, 2020 – 2027
      12. Others
      13. Market Estimates & Forecast, 2020 – 2027
    3. Chapter 7. Global Silent Heart Attack Market, by Treatment
      1. Introduction
      2. Medications
      3. Market Estimates & Forecast, 2020 – 2027
      4. Coronary angioplasty and stenting
      5. Market Estimates & Forecast, 2020 – 2027
      6. Coronary artery bypass surgery
      7. Market Estimates & Forecast, 2020 – 2027
      8. Other
      9. Market Estimates & Forecast, 2020 – 2027
    4. Chapter 8 Global Silent Heart Attack Market, by End User
      1. Introduction
      2. Hospital
      3. Market Estimates & Forecast, 2020 – 2027
      4. Clinics
      5. Market Estimates & Forecast, 2020 – 2027
      6. Diagnostic Centers
      7. Market Estimates & Forecast, 2020 – 2027
      8. Others
      9. Market Estimates & Forecast, 2020 – 2027
    5. Chapter 9. Global Silent Heart Attack Market, by Region
      1. Introduction
      2. America
        1. North America
        2. South America
      3. Europe
        1. Western Europe
        2. Eastern Europe
      4. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia
        5. Republic of Korea
        6. Rest of Asia Pacific
      5. The Middle East & Africa
        1. United Arab Emirates
        2. Saudi Arabia
        3. Oman
        4. Kuwait
        5. Qatar
        6. Rest of the Middle East & Africa
      6. Chapter 10 Company Landscape
      7. Introduction
      8. Market Share Analysis
      9. Key Development & Strategies
        1. Key Developments
      10. Chapter 11 Company Profiles
      11. Siemens
        1. Company Overview
        2. Product Overview
        3. Financials
        4. SWOT Analysis
      12. Koninklijke Philips N.V.
        1. Company Overview
        2. Product Overview
        3. Financial Overview
        4. Key Developments
        5. SWOT Analysis
      13. AstraZeneca plc
        1. Company Overview
        2. Product Overview
        3. Financial Overview
        4. Key Development
        5. SWOT Analysis
      14. Pfizer
        1. Company Overview
        2. Product/Business Segment Overview
        3. Financial Overview
        4. Key Development
        5. SWOT Analysis
      15. Sanofi
        1. Company Overview
        2. Product Overview
        3. Financial overview
        4. Key Developments
      16. Merck & Co.
        1. Company Overview
        2. Product Overview
        3. Financial Overview
        4. Key Developments
      17. F. Hoffmann-La Roche Ltd.
        1. Overview
        2. Product Overview
        3. Financials
        4. Key Developments
        5. SWOT Analysis
      18. Others
      19. Chapter 12 MRFR Conclusion
      20. Key Findings
        1. From CEO’s View Point
        2. Unmet Needs of the Market
      21. Key Companies to Watch
      22. Prediction of Pharmaceutical industry
      23. Chapter 13 Appendix
    6. LIST OF TABLES
    7. Silent Heart Attack Industry Synopsis, 2020 – 2027
    8. Global Silent Heart Attack Market Estimates and Forecast, 2020 – 2027, (USD Million)
    9. Global Silent Heart Attack Market by Region, 2020 – 2027, (USD Million)
    10. Global Silent Heart Attack Market by Diagnosis, 2020 – 2027, (USD Million)
    11. Global Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    12. Global Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    13. North America Silent Heart Attack Market by Diagnosis, 2020 – 2027, (USD Million)
    14. North America Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    15. North America Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    16. US Market by Diagnosis, 2020 – 2027, (USD Million)
    17. US Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    18. US Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    19. Canada Market by Diagnosis, 2020 – 2027, (USD Million)
    20. Canada Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    21. Canada Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    22. South America Market by Diagnosis, 2020 – 2027, (USD Million)
    23. South America Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    24. South America Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    25. Europe Market by Diagnosis, 2020 – 2027, (USD Million)
    26. Europe Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    27. Europe Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    28. Western Europe Market by Diagnosis, 2020 – 2027, (USD Million)
    29. Western Europe Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    30. Western Europe Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    31. Eastern Europe Market by Diagnosis, 2020 – 2027, (USD Million)
    32. Eastern Europe Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    33. Eastern Europe Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    34. Asia Pacific Market by Diagnosis, 2020 – 2027, (USD Million)
    35. Asia Pacific Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    36. Asia Pacific Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    37. Middle East & Africa Market by Diagnosis, 2020 – 2027, (USD Million)
    38. Middle East & Africa Silent Heart Attack Market by Treatment, 2020 – 2027, (USD Million)
    39. Middle East & Africa Silent Heart Attack Market by End Users, 2020 – 2027, (USD Million)
    40. LIST OF FIGURES
    41. Research Process
    42. Segmentation for Global Silent Heart Attack Market
    43. Segmentation Market Dynamics for Global Silent Heart Attack Market
    44. Global Silent Heart Attack market Share, by Type 2020
    45. Global Silent Heart Attack market Share, by Treatment 2020
    46. Global Silent Heart Attack Market Share, by End Users, 2020
    47. Global Silent Heart Attack Market Share, by Region, 2020
    48. North America Silent Heart Attack Market Share, by Country, 2020
    49. Europe Silent Heart Attack Market Share, by Country, 2020
    50. Asia Pacific Silent Heart Attack Market Share, by Country, 2020
    51. Middle East & Africa Silent Heart Attack Market Share, by Country, 2020
    52. Global Silent Heart Attack Market: Company Share Analysis, 2020 (%)
    53. Siemens: Key Financials
    54. Siemens: Segmental Revenue
    55. Siemens: Geographical Revenue
    56. Koninklijke Philips N.V.: Key Financials
    57. Koninklijke Philips N.V.: Segmental Revenue
    58. Koninklijke Philips N.V.: Geographical Revenue
    59. AstraZeneca plc: Key Financials
    60. AstraZeneca plc: Segmental Revenue
    61. AstraZeneca plc: Geographical Revenue
    62. Pfizer: Key Financials
    63. Pfizer: Segmental Revenue
    64. Pfizer: Geographical Revenue
    65. Sanofi.: Key Financials
    66. Sanofi.: Segmental Revenue
    67. Sanofi.: Geographical Revenue
    68. F. Hoffmann-La Roche Ltd.: Key Financials
    69. F. Hoffmann-La Roche Ltd.: Segmental Revenue
    70. F. Hoffmann-La Roche Ltd.: Geographical Revenue
    71. AstraZeneca Plc: Key Financials
    72. AstraZeneca Plc: Segmental Revenue
    73. AstraZeneca Plc.: Geographical Revenue

    Silent Heart Attack Market Segmentation

    Market Segmentation Overview

    • Detailed segmentation data will be available in the full report
    • Comprehensive analysis by multiple parameters
    • Regional and country-level breakdowns
    • Market size forecasts by segment
    Infographic

    Free Sample Request

    Kindly complete the form below to receive a free sample of this Report

    Get Free Sample

    Customer Strories

    “I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

    Victoria Milne

    Founder
    Case Study
    Chemicals and Materials

    Compare Licence

    ×
    Features License Type
    Single User Multiuser License Enterprise User
    Price $4,950 $5,950 $7,250
    Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
    Free Customization
    Direct Access to Analyst
    Deliverable Format
    Platform Access
    Discount on Next Purchase 10% 15% 15%
    Printable Versions